This is the text extract for Notification of agreement with Pfizer, browse documents here.

---

4 December 2009

Approval of agreement with Pfizer New Zealand Ltd for clindamycin (Dalacin C), sulphasalazine (Salazopyrin), cabergoline (Dostinex) and medroxyprogesterone (Provera and Depo-Provera)

PHARMAC is pleased to announce the approval of an agreement with Pfizer New Zealand Limited for the supply of clindamycin (Dalacin C), sulphasalazine (Salazopyrin), cabergoline (Dostinex) and medroxyprogesterone (Provera and Depo-Provera). This was the subject of a consultation letter dated 29 October 2009. In summary, the agreement involves subsidy and price changes for all of the above pharmaceuticals in return for protection from subsidy and/or delisting protection and/or Hospital Supply Status over various periods. Further details of the decision can be found below. Details of the decision Clindamycin Injection • The price and subsidy (ex-manufacturer, excluding GST) for clindamycin injection (Dalacin C) will be reduced in Section B and in Part II of Section H of the Pharmaceutical Schedule from 1 January 2010 as follows:

Chemical

Formulation Inj phosphate 150 mg per ml, 4 ml

Brand

Pack size 1

Current price and subsidy $19.45

New price and subsidy $16.00

Clindamycin

Dalacin C

•

Dalacin C will have Hospital Supply Status and protection from delisting and subsidy reduction until 30 June 2013.

Cabergoline • The prices and subsidies (ex-manufacturer, excluding GST) for cabergoline tablets (Dostinex) will be reduced in Section B of the Pharmaceutical Schedule from 1 January 2010 as follows:

Current price and subsidy $26.26 $105.03

Chemical Cabergoline Cabergoline

Formulation

Brand Dostinex Dostinex

Pack size 2 8

New price and subsidy $16.50 $66.00

Tab 0.5 mg

•

Dostinex will have protection from delisting and subsidy reduction until 30 June 2012.

A324195 - T09-376 Page 1 of 3

---

Medroxyprogesterone acetate • The price and subsidy (ex-manufacturer, excluding GST) for medroxyprogesterone acetate (Depo-Provera) will be reduced in Section B of the Pharmaceutical Schedule from 1 January 2010 as follows:

Current price and subsidy $8.05 New price and subsidy $7.15

Chemical Medroxyprogesterone acetate

Formulation Inj 150 mg per ml, 1 ml, syringe

Brand DepoProvera

Pack size 1

• •

Medroxyprogesterone acetate injection (Depo-Provera) will be listed in Part II of Section H of the Pharmaceutical Schedule from 1 January 2010 at the above prices. The prices and subsidies (ex-manufacturer, excluding GST) for medroxyprogesterone acetate (Provera) will be amended in Section B and in Part II of Section H of the Pharmaceutical Schedule from 1 January 2010 as follows:

Current price and subsidy $2.07 $13.75 $7.57 $104.26 $78.06 New price and subsidy $3.09 $13.06 $6.85 $96.50 $70.50

Chemical Medroxyprogesterone acetate Medroxyprogesterone acetate Medroxyprogesterone acetate Medroxyprogesterone acetate Medroxyprogesterone acetate

Formulation

Brand

Pack size

Tab 2.5 mg Tab 5 mg Tab 10 mg Tab 100 mg Tab 200 mg

Provera Provera Provera Provera Provera

30 100 30 100 30

•

Provera and Depo-Provera will each have Hospital Supply Status and protection from delisting and subsidy reduction until 30 June 2013.

A324195 - T09-376 Page 2 of 3

---

Sulphasalazine • The prices and subsidies (ex-manufacturer, excluding GST) for sulphasalazine tablets (Salazopyrin and Salazopyrin EN) will be increased in Section B of the Pharmaceutical Schedule from 1 March 2010 as follows:

Current price and subsidy $8.42 $9.44

Chemical Sulphasalazine Sulphasalazine

Formulation Tab 500 mg Tab 500 mg enteric coated

Brand Salazopyrin Salazopyrin EN

Pack size 100 100

New price and subsidy $11.68 $12.89

• •

Salazopyrin and Salazopyrin EN will be listed in Part II of Section H of the Pharmaceutical Schedule from 1 March 2010 at the above prices. Salazopyrin and Salazopyrin EN will have protection from delisting and subsidy reduction until 1 July 2013.

Feedback received We appreciate all of the feedback that we received and acknowledge the time people took to respond. All consultation responses received by 12 November 2009 were considered in their entirety in making a decision on the changes. All responses were supportive of the proposal and no issues with the proposal were raised.

More information If you have any questions about this decision, you can call our toll free number (9 am to 5 pm, Monday to Friday) on 0800 66 00 50.

A324195 - T09-376 Page 3 of 3